In TNBC immunotherapy targeting PD1/PDL-1, in addition to research and development of new targeted antibodies, studies have found that tumor-associated macrophages (TAMs) derived from peripheral-blood mononuclear cells were recruited into the TNBC microenvironment. This evidence concerns the gene CD274 and neoplasm.